Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
US Army
Cerilliant
Baxter
Julphar
Johnson and Johnson
Dow
Cipla
Farmers Insurance

Generated: January 20, 2018

DrugPatentWatch Database Preview

Pancrelipase (amylase;lipase;protease) - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pancrelipase (amylase;lipase;protease) and what is the scope of pancrelipase (amylase;lipase;protease) patent protection?

Pancrelipase (amylase;lipase;protease)
is the generic ingredient in seven branded drugs marketed by Abbvie, Janssen Pharms, Digestive Care Inc, Forest Labs Inc, and Organon Usa Inc, and is included in seven NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pancrelipase (amylase;lipase;protease) has eighty-two patent family members in thirty countries.

There are six drug master file entries for pancrelipase (amylase;lipase;protease). Eight suppliers are listed for this compound.
Summary for pancrelipase (amylase;lipase;protease)
International Patents:82
US Patents:8
Tradenames:7
Applicants:5
NDAs:7
Drug Master File Entries: 6
Suppliers / Packagers: 8
Clinical Trials: 800
Drug Prices:see low prices
DailyMed Link:pancrelipase (amylase;lipase;protease) at DailyMed

US Patents and Regulatory Information for pancrelipase (amylase;lipase;protease)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-002 Aug 27, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-003 Aug 27, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-001 Aug 27, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Janssen Pharms PANCREAZE pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022523-002 Apr 12, 2010 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-005 Jun 15, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-006 Jul 13, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-007 Mar 25, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-001 Aug 27, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-005 Jun 15, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms PANCREAZE pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022523-005 Mar 7, 2014 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for pancrelipase (amylase;lipase;protease)

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,229 Methods of producing stable pancreatic enzyme compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for pancrelipase (amylase;lipase;protease)

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Accenture
QuintilesIMS
McKesson
Medtronic
US Department of Justice
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot